- Home
- FLR vs PTGX Comparison
FLR vs PTGX Comparison
Compare FLR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLR | PTGX |
|---|---|---|
| Founded | 1912 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.4B |
| IPO Year | 2006 | 2016 |
Fundamental Metrics
Financial Performance| Metric | FLR | PTGX |
|---|---|---|
| Price | $49.14 | $105.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $53.50 | ★ $108.23 |
| AVG Volume (30 Days) | ★ 2.7M | 483.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.08 | 0.05 |
| Revenue | ★ $15,503,000,000.00 | N/A |
| Revenue This Year | $6.56 | $874.25 |
| Revenue Next Year | $7.10 | N/A |
| P/E Ratio | ★ $45.84 | $1,960.60 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $37.62 | $49.86 |
| 52 Week High | $57.50 | $107.84 |
Technical Indicators
Market Signals| Indicator | FLR | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 57.98 |
| Support Level | $44.88 | $94.48 |
| Resistance Level | $50.58 | N/A |
| Average True Range (ATR) | 2.13 | 4.69 |
| MACD | 0.47 | 0.37 |
| Stochastic Oscillator | 75.79 | 99.02 |
Price Performance
Historical ComparisonAbout FLR Fluor Corporation
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services. It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $15.5 billion in revenue in 2025.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.